{"name":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.","slug":"shanghai-fudan-zhangjiang-bio-pharmaceutical-co-ltd","ticker":"","exchange":"","domain":"shanghaifudanzhangjiangbio.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"oncology","drugs":[{"name":"ALA 5%","genericName":"ALA 5%","slug":"ala-5","indication":"Other","status":"phase_1"},{"name":"ALA 10%","genericName":"ALA 10%","slug":"ala-10","indication":"Other","status":"phase_1"},{"name":"ALA 2.5%","genericName":"ALA 2.5%","slug":"ala-2-5","indication":"Other","status":"phase_1"},{"name":"Hemoporfin","genericName":"Hemoporfin","slug":"hemoporfin","indication":"Other","status":"marketed"},{"name":"deuteporfin","genericName":"deuteporfin","slug":"deuteporfin","indication":"Other","status":"phase_1"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"immunology","drugs":[{"name":"Aminolaevulinic acid","genericName":"Aminolaevulinic acid","slug":"aminolaevulinic-acid","indication":"Actinic keratosis","status":"phase_2"},{"name":"Aminolaevulinic acid photodynamic therapy","genericName":"Aminolaevulinic acid photodynamic therapy","slug":"aminolaevulinic-acid-photodynamic-therapy","indication":"Actinic keratosis","status":"phase_2"},{"name":"Doxorubicin hydrochloride liposome","genericName":"Doxorubicin hydrochloride liposome","slug":"doxorubicin-hydrochloride-liposome","indication":"Metastatic breast cancer","status":"marketed"},{"name":"FDA018-ADC","genericName":"FDA018-ADC","slug":"fda018-adc","indication":"Solid tumors (specific indication under investigation in Phase 3)","status":"phase_3"},{"name":"Hemoporfin PDT","genericName":"Hemoporfin PDT","slug":"hemoporfin-pdt","indication":"Esophageal cancer","status":"marketed"}]}],"pipeline":[{"name":"ALA 5%","genericName":"ALA 5%","slug":"ala-5","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ALA 10%","genericName":"ALA 10%","slug":"ala-10","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ALA 2.5%","genericName":"ALA 2.5%","slug":"ala-2-5","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Aminolaevulinic acid","genericName":"Aminolaevulinic acid","slug":"aminolaevulinic-acid","phase":"phase_2","mechanism":"Aminolaevulinic acid is a precursor to porphobilinogen, which is involved in the biosynthesis of heme.","indications":["Actinic keratosis","Basal cell carcinoma"],"catalyst":""},{"name":"Aminolaevulinic acid photodynamic therapy","genericName":"Aminolaevulinic acid photodynamic therapy","slug":"aminolaevulinic-acid-photodynamic-therapy","phase":"phase_2","mechanism":"Aminolaevulinic acid acts as a precursor to porphyrin, which accumulates in cancer cells and is activated by light to produce reactive oxygen species, inducing cell death.","indications":["Actinic keratosis","Basal cell carcinoma"],"catalyst":""},{"name":"Doxorubicin hydrochloride liposome","genericName":"Doxorubicin hydrochloride liposome","slug":"doxorubicin-hydrochloride-liposome","phase":"marketed","mechanism":"Doxorubicin hydrochloride liposome is a chemotherapy agent encapsulated in liposomes that intercalates into DNA and inhibits topoisomerase II, delivered via liposomal nanoparticles to improve tumor targeting and reduce systemic toxicity.","indications":["Metastatic breast cancer","Ovarian cancer","Multiple myeloma","Kaposi sarcoma"],"catalyst":""},{"name":"FDA018-ADC","genericName":"FDA018-ADC","slug":"fda018-adc","phase":"phase_3","mechanism":"FDA018-ADC is an antibody-drug conjugate that delivers cytotoxic payload to target cells expressing specific tumor antigens.","indications":["Solid tumors (specific indication under investigation in Phase 3)"],"catalyst":""},{"name":"Hemoporfin","genericName":"Hemoporfin","slug":"hemoporfin","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Hemoporfin PDT","genericName":"Hemoporfin PDT","slug":"hemoporfin-pdt","phase":"marketed","mechanism":"Hemoporfin is a photosensitizer that generates reactive oxygen species upon light activation to destroy tumor cells in photodynamic therapy.","indications":["Esophageal cancer","Gastric cancer","Bladder cancer","Endobronchial tumors"],"catalyst":""},{"name":"deuteporfin","genericName":"deuteporfin","slug":"deuteporfin","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMitgJBVV95cUxNLW9aVk4temIzM294eVFyMFlCVHJFWmxOdkZvYkI2M1lwS0tod3FRSHpEZDBWODU5Q1drdmlnd0IwVms4bFVlT0tVZ2JrM1B3c0NrOEJrcjdiY0wwQ2ZkSm9FUTBMQnN3TG1CN09CaXEtUTR4N2ZxVFUyUHJRX3haamxhZ1JEaWI3azhlTjhmcW5xcnQ1N0ptMTJzOXdUelVWTms1allOc0c5WGZrbUpZTndIZHcxVG1fdWRNbWFtR25jb2h2dzFGOWNGYmJqbzRubGh3Skw3VUo5NHQ3SVhpRXBWNlFkd2NSc01kbnpQY0ZUOXhWVU5xUmgxUkFjbXNHelBDazFlNDNHQ09QeUswQWVOQW5CX01DcXVTbEU5eUZpb1RRZS1sQjlfa1dSY2NoWjVoYTl3?oc=5","date":"2026-04-01","type":"pipeline","source":"GlobeNewswire","summary":"Liposomal Doxorubicin Market Insights Report 2026: Cancer - GlobeNewswire","headline":"Liposomal Doxorubicin Market Insights Report 2026: Cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxNelRlX1ZBZE1uajZBcjIzY3lySmktancxUGFCWlZJMFFkc1VuS1dXUmRwZlZVRGg0UlJGMm54WXAyOVVWR1RUM0oyOW9RNXEzbW9VUF9GLTJ4SXp0aTZFX29yYkUyZEF5V1JPZkR4YmJTdUFjYXpUVkJvM3JKWi1weElmQkE0YjE1LUJ4MURkNk9rY0ViUVd6ZkZGOWYxUQ?oc=5","date":"2026-04-01","type":"pipeline","source":"openPR.com","summary":"Leading Companies Reinforcing Their Presence in the Liposomal Drug Delivery Devices Market - openPR.com","headline":"Leading Companies Reinforcing Their Presence in the Liposomal Drug Delivery Devices Market","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxOZmJEeS1EbndQWGpSczlMd0Q2dlB3QkJDWUVtaG1nT2ZXUHZ3TUoyR1BGTHctN2lMblNPWk9ITmdGR1hFRXhqcXFPd2pteXA0ajQwOHQ3M1lWcGpvcnpDcV9ZbGx6bEREOWc2cjBQSVRsTHZGZEI5bmxjSHdOTHdYVm13X1VRSHFFa0FobXFTQzNDN25iQkFpUmxwNV9xdw?oc=5","date":"2026-03-20","type":"pipeline","source":"openPR.com","summary":"High-Grade Glioma Treatment Pipeline Shows Strong Momentum as - openPR.com","headline":"High-Grade Glioma Treatment Pipeline Shows Strong Momentum as","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxQVFQ0YlpTSHFJdGdjaUJvRENzX0w1R1ViMUVCUUN0bzBtQnFHN2V6S1dCV0RmM2dJS3RkQ2cyNUl1YXA4VkFPbFhCMTlpWjNJeTR0cnIwUW9aQTltVE10dnZVX21NX2pWR0UzMXdvYjVyX1ZvR29mOVIxQXZIRW16RmJFX0RWaVdvaEIydG9RcVVFQy1SaHpXRWwxMFo0am9ieVBtVE11T3JZYXRobFVsOHdyQ0I2WW9DRGVZXy1n?oc=5","date":"2026-02-20","type":"pipeline","source":"BioWorld News","summary":"Shanghai Fudan Zhangjiang Biopharmaceutical synthesizes new compounds for cancer - BioWorld News","headline":"Shanghai Fudan Zhangjiang Biopharmaceutical synthesizes new compounds for cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxQZlB0QkN5aXIyYjI0eGZfZ0RRbHVUc0lSVEdscE9zV1YzUnZlQzJuN0x2QnozUEZMYm1aTjl4SFJydzdURkRYWURLeXdwRGFpUjlwZ1ZQYm9yYnNRN3dIeUgyZC11eEdqOGZESnNwTkp3NGdPendWWTNRTUxXVUZjV0dGVXplRmtM?oc=5","date":"2026-02-11","type":"pipeline","source":"Yahoo Finance","summary":"Global Market Insights: Penny Stocks To Watch In February 2026 - Yahoo Finance","headline":"Global Market Insights: Penny Stocks To Watch In February 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxOcUlQTUJfYUhhNk9VZXNXQ3JWYlExd0hqYzkyOW5HV2htMmlzQXE1akZKbFJFTzNHTmo4VWVjdFctUjZfRW1mOGVPcmdIcDdJTzhZSW5YWTB5VURpWlFPTG9Sd05OS0pnTWpkc3RQdDdmSXo0T2F5eVhINHc4MF8tUTVyXzBMTHpRZEk1blZ0SkV1YWFXaE1TRVEwRVJ6Q3B3MlJoTC1fWnJmQ21SQ0MydFIwMjNlMWpXS08tZ01paU9Da2QyRUtCdU94cWFEQ1N6enNURGQ3WGstNWxieVVlblNteHM2OVd0M3c?oc=5","date":"2025-02-04","type":"pipeline","source":"PR Newswire","summary":"Global Peptide-Drug Conjugate Market to Show Enormous Growth at a CAGR of ~29% by 2032 | DelveInsight - PR Newswire","headline":"Global Peptide-Drug Conjugate Market to Show Enormous Growth at a CAGR of ~29% by 2032 | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxQd3lYXzYzUkhZWXhnTkNXczRIaDB2dXc3cmgybXVOaTRQUjZUMEphSUptS1FBajBTSEFPN3h4aEVIVUlqSXdxSy12alhrUl9JZExfTDdmTzB3NHYtN0J6ZTExTWpreE9adEFwVU5pU0diSFM1OUxvRHlnbkdCZEo2UnhwclF4emItLWJtczZISS1yNlNIaTk2c0dRTC1PZi1CZ0VFXzNFZ2NWc2pa?oc=5","date":"2024-12-30","type":"trial","source":"BioWorld News","summary":"Ideaya, Hengrui join hands in $1B deal for phase I ADC targeting DLL3 - BioWorld News","headline":"Ideaya, Hengrui join hands in $1B deal for phase I ADC targeting DLL3","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAJBVV95cUxOZTZENWlBcGdoX3lFM3RReUhXdFpwRmtnZUN4RG5Va3lwU1JTdFNCcm82VkxfWmhmakwwNU1XMUVSQ2dzSnhxRkNycW5xZVc4OHk4X3lwZ0NoQXhQUm51c1lMaVB3RFVTVFA1MTFEY0ppelZGOWZZMVlhZ2t0ZTNQX0t5SEt1amh0TV9OUFZxbWpMNGZWVWtNSXd6QzRCOWRrRU9ucU9OWlU4SVZKMUliVzNPdFl1R044T29zMmNMS0Y3MmNCb2xMV201UDR2WDRDZ0hmUzRrQld2OUxZaVh0d2phTWY2Y25aQ0dlWnBRckVqRzVLVzNPU1RzSmxIbklqaU5KVkxNSEVEaUUxeDBUM1pCc2NhWUZyQUY5ZQ?oc=5","date":"2024-10-29","type":"pipeline","source":"PR Newswire","summary":"Nanoparticle Drug Delivery Systems Market to Grow by USD 54.90 Billion (2024-2028) Driven by Chronic Diseases and AI Trends, Says Technavio - PR Newswire","headline":"Nanoparticle Drug Delivery Systems Market to Grow by USD 54.90 Billion (2024-2028) Driven by Chronic Diseases and AI Tre","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_AFBVV95cUxOM21NWGJUU3VHRnF1NzFjNk1RelV4RGVxWXVYN19jNGhVNjZIekt5YktjYTRBejRQeGE2VWd6V0RESG92eldPZms4RDlFZ0kxWmdtb0Z2ODFtR1ZTQWJCM0Nha0p4YXhoazJrdV9rYzVUVDlxTnAyVXRMOTdkeTR1S3ZyMDJ3TW4xU3lQa0pNY1dzeGt1R0E4Xy14bFlISWJkck1WRUdDMTFzOW5YOWlHalB5ZmpZcWR2dGxNNTEzbGhyUklaZWtWMG9fTWU1NGtPRWRIS3AyanphRFhaYmQtTGRIX21YNkRKYS1aUDNRbFFjWnN3Ti1GX3JOc3Y?oc=5","date":"2024-10-17","type":"pipeline","source":"PR Newswire","summary":"200+ Pharma Companies Vie for the Top Spot in the Expanding Antibody-Drug Conjugate Oncology Market | DelveInsight - PR Newswire","headline":"200+ Pharma Companies Vie for the Top Spot in the Expanding Antibody-Drug Conjugate Oncology Market | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVkFVX3lxTE9ZR0RlRlN3NExkZjl6T0ZZTEktTnFWZDd5YjJYdkZFbXpOUm5XNnhmVldJajhvNk1YRkNpOVd1NnQ1eGdTdFVNWTVUdWZVZHhvMHNFa3Nn?oc=5","date":"2017-06-12","type":"pipeline","source":"Yahoo Finance Singapore","summary":"Jacobson Pharma Corporation Limited (2633.HK) stock price, news, quote and history - Yahoo Finance Singapore","headline":"Jacobson Pharma Corporation Limited (2633.HK) stock price, news, quote and history","sentiment":"neutral"}],"patents":[],"drugCount":10,"phaseCounts":{"phase_1":4,"phase_2":2,"marketed":3,"phase_3":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}